<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Neuropharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Neuropharmacol</journal-id><journal-id journal-id-type="publisher-id">WNF</journal-id><journal-title-group><journal-title>Clinical Neuropharmacology</journal-title></journal-title-group><issn pub-type="ppub">0362-5664</issn><issn pub-type="epub">1537-162X</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29432286</article-id><article-id pub-id-type="pmc">5865491</article-id><article-id pub-id-type="publisher-id">WNF50187</article-id><article-id pub-id-type="doi">10.1097/WNF.0000000000000269</article-id><article-id pub-id-type="art-access-id">00001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>LeWitt</surname><given-names>Peter A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name><surname>Verhagen Metman</surname><given-names>Leo</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">†</xref></contrib><contrib contrib-type="author"><name><surname>Rubens</surname><given-names>Robert</given-names></name><degrees>MD, MBA</degrees><xref ref-type="aff" rid="aff1">‡</xref></contrib><contrib contrib-type="author"><name><surname>Khanna</surname><given-names>Sarita</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">‡</xref></contrib><contrib contrib-type="author"><name><surname>Kell</surname><given-names>Sherron</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">‡</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Suneel</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">‡</xref></contrib></contrib-group><aff id="aff1">*Henry Ford Hospital and Wayne State University School of Medicine, West Bloomfield, MI; †Rush University Medical Center, Chicago, IL; and ‡Impax Laboratories, Inc, Hayward, CA.</aff><author-notes><corresp id="cor1">Address correspondence and reprint requests to Peter A. LeWitt, MD, Henry Ford Hospital, 6777 W Maple Rd, West Bloomfield, MI 48322; E-mail: <email>plewitt1@hfhs.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2018</year></pub-date><volume>41</volume><issue>2</issue><fpage>47</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Wolters Kluwer Health, Inc. All rights reserved.</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="wnf-41-47.pdf"></self-uri><abstract><sec><title><offsets xml_i="3867" xml_f="3877" txt_i="11" txt_f="21">Objectives</offsets></title><p><offsets xml_i="3888" xml_f="4434" txt_i="22" txt_f="568">Extended-release (ER) carbidopa-levodopa (CD-LD) (IPX066/RYTARY/NUMIENT) produces improvements in “off” time, “on” time without troublesome dyskinesia, and Unified Parkinson Disease Rating Scale scores compared with immediate-release (IR) CD-LD or IR CD-LD plus entacapone (CLE). Post hoc analyses of 2 ER CD-LD phase 3 trials evaluated whether the efficacy and safety of ER CD-LD relative to the respective active comparators were altered by concomitant medications (dopaminergic agonists, monoamine oxidase B [MAO-B] inhibitors, or amantadine).</offsets></p></sec><sec><title><offsets xml_i="4456" xml_f="4463" txt_i="570" txt_f="577">Methods</offsets></title><p><offsets xml_i="4474" xml_f="5150" txt_i="578" txt_f="1254">ADVANCE-PD (n = 393) assessed safety and efficacy of ER CD-LD versus IR CD-LD. ASCEND-PD (n = 91) evaluated ER CD-LD versus CLE. In both studies, IR- and CLE-experienced patients underwent a 6-week, open-label dose-conversion period to ER CD-LD prior to randomization. For analysis, the randomized population was divided into 3 subgroups: dopaminergic agonists, rasagiline or selegiline, and amantadine. For each subgroup, changes from baseline in PD diary measures (“off” time and “on” time with and without troublesome dyskinesia), Unified Parkinson Disease Rating Scale Parts II + III scores, and adverse events were analyzed, comparing ER CD-LD with the active comparator.</offsets></p></sec><sec><title><offsets xml_i="5172" xml_f="5195" txt_i="1256" txt_f="1279">Results and Conclusions</offsets></title><p><offsets xml_i="5206" xml_f="5803" txt_i="1280" txt_f="1877">Concomitant dopaminergic agonist or MAO-B inhibitor use did not diminish the efficacy (improvement in “off” time and “on” time without troublesome dyskinesia) of ER CD-LD compared with IR CD-LD or CLE, whereas the improvement with concomitant amantadine failed to reach significance. Safety and tolerability were similar among the subgroups, and ER CD-LD did not increase troublesome dyskinesia. For patients on oral LD regimens and taking a dopaminergic agonist, and/or a MAO-B inhibitor, changing from an IR to an ER CD-LD formulation provides approximately an additional hour of “good” on time.</offsets></p></sec></abstract><kwd-group><title>Key Words</title><kwd>amantadine</kwd><kwd>dopaminergic agonist</kwd><kwd>extended release</kwd><kwd>levodopa</kwd><kwd>monoamine oxidase inhibitor</kwd></kwd-group><counts><page-count count="0"></page-count></counts><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="6220" xml_f="6429" txt_i="1886" txt_f="2095">Oral levodopa (LD) administered in combination with a peripherally active decarboxylase inhibitor such as carbidopa (CD) is the most widely used therapy for the symptomatic treatment of Parkinson disease (PD).</offsets><sup><xref rid="bib1" ref-type="bibr"><offsets xml_i="6467" xml_f="6468" txt_i="2095" txt_f="2096">1</offsets></xref></sup><offsets xml_i="6481" xml_f="6773" txt_i="2096" txt_f="2388"> However, prolonged use of LD and/or progression of the disease is often associated with the development of motor fluctuations, including end-of-dose “wearing off” and dyskinesia. Mechanisms leading to the development of the various patterns of motor fluctuations are incompletely understood,</offsets><sup><xref rid="bib2" ref-type="bibr"><offsets xml_i="6811" xml_f="6812" txt_i="2388" txt_f="2389">2</offsets></xref></sup><offsets xml_i="6825" xml_f="6946" txt_i="2389" txt_f="2510"> although there is evidence suggesting that pulsatile stimulation of dopamine receptors in the basal ganglia is involved.</offsets><sup><xref rid="bib3" ref-type="bibr"><offsets xml_i="6984" xml_f="6985" txt_i="2510" txt_f="2511">3</offsets></xref><offsets xml_i="6992" xml_f="6993" txt_i="2511" txt_f="2512">,</offsets><xref rid="bib4" ref-type="bibr"><offsets xml_i="7026" xml_f="7027" txt_i="2512" txt_f="2513">4</offsets></xref></sup><offsets xml_i="7040" xml_f="7307" txt_i="2513" txt_f="2780"> Several pharmacological strategies have been used to achieve more sustained plasma LD concentrations to manage, and possibly avoid, motor fluctuations associated with oral LD. These include the use of extended-release (ER) LD formulations and inhibitors of catechol-</offsets><italic><offsets xml_i="7315" xml_f="7316" txt_i="2780" txt_f="2781">O</offsets></italic><offsets xml_i="7325" xml_f="7383" txt_i="2781" txt_f="2839">-methyltransferase (COMT) and monoamine oxidase B (MAO-B).</offsets><sup><xref rid="bib5" ref-type="bibr"><offsets xml_i="7421" xml_f="7422" txt_i="2839" txt_f="2840">5</offsets></xref><offsets xml_i="7429" xml_f="7430" txt_i="2840" txt_f="2841">,</offsets><xref rid="bib6" ref-type="bibr"><offsets xml_i="7463" xml_f="7464" txt_i="2841" txt_f="2842">6</offsets></xref></sup></p><p><offsets xml_i="7484" xml_f="7680" txt_i="2843" txt_f="3039">In advanced PD, available adjunctive therapies can reduce “off” time associated with LD therapy, which in some studies exceeds 6 hours per day. In placebo-controlled studies, dopaminergic agonists</offsets><sup><xref rid="bib7" ref-type="bibr"><offsets xml_i="7718" xml_f="7719" txt_i="3039" txt_f="3040">7</offsets></xref><offsets xml_i="7726" xml_f="7727" txt_i="3040" txt_f="3041">–</offsets><xref rid="bib13" ref-type="bibr"><offsets xml_i="7761" xml_f="7763" txt_i="3041" txt_f="3043">13</offsets></xref></sup><offsets xml_i="7776" xml_f="7800" txt_i="3043" txt_f="3067"> and inhibitors of MAO-B</offsets><sup><xref rid="bib14" ref-type="bibr"><offsets xml_i="7839" xml_f="7841" txt_i="3067" txt_f="3069">14</offsets></xref><offsets xml_i="7848" xml_f="7849" txt_i="3069" txt_f="3070">–</offsets><xref rid="bib16" ref-type="bibr"><offsets xml_i="7883" xml_f="7885" txt_i="3070" txt_f="3072">16</offsets></xref></sup><offsets xml_i="7898" xml_f="8204" txt_i="3072" txt_f="3378"> have been shown to produce clinically meaningful reductions in “off” time as measured by patient home diaries and improved scores in the activities of daily living (Part II) and motor examination scores (Part III) of the Unified Parkinson Disease Rating Scale (UPDRS). Amantadine, a nonspecific glutamate </offsets><italic><offsets xml_i="8212" xml_f="8213" txt_i="3378" txt_f="3379">N</offsets></italic><offsets xml_i="8222" xml_f="8230" txt_i="3379" txt_f="3387">-methyl-</offsets><sc><offsets xml_i="8234" xml_f="8235" txt_i="3387" txt_f="3388">d</offsets></sc><offsets xml_i="8240" xml_f="8331" txt_i="3388" txt_f="3479">-aspartate receptor antagonist, reduces the severity and duration of LD-induced dyskinesia.</offsets><sup><xref rid="bib4" ref-type="bibr"><offsets xml_i="8369" xml_f="8370" txt_i="3479" txt_f="3480">4</offsets></xref><offsets xml_i="8377" xml_f="8378" txt_i="3480" txt_f="3481">,</offsets><xref rid="bib17" ref-type="bibr"><offsets xml_i="8412" xml_f="8414" txt_i="3481" txt_f="3483">17</offsets></xref><offsets xml_i="8421" xml_f="8422" txt_i="3483" txt_f="3484">–</offsets><xref rid="bib19" ref-type="bibr"><offsets xml_i="8456" xml_f="8458" txt_i="3484" txt_f="3486">19</offsets></xref></sup><offsets xml_i="8471" xml_f="8787" txt_i="3486" txt_f="3802"> A Cochrane Collaboration meta-analysis of efficacy and safety studies investigated adjunct oral treatments for PD patients with motor complications who were on stable immediate-release (IR) oral LD regimens and found that dopaminergic agonists were more effective at controlling parkinsonian symptoms than catechol-</offsets><italic><offsets xml_i="8795" xml_f="8796" txt_i="3802" txt_f="3803">O</offsets></italic><offsets xml_i="8805" xml_f="8925" txt_i="3803" txt_f="3923">-methyltransferase inhibitors or MAO-B inhibitors. The overall incidence of side effects was similar among the 3 groups.</offsets><sup><xref rid="bib20" ref-type="bibr"><offsets xml_i="8964" xml_f="8966" txt_i="3923" txt_f="3925">20</offsets></xref></sup><offsets xml_i="8979" xml_f="9033" txt_i="3925" txt_f="3979"> Current treatment guidelines reflect this conclusion.</offsets><sup><xref rid="bib6" ref-type="bibr"><offsets xml_i="9071" xml_f="9072" txt_i="3979" txt_f="3980">6</offsets></xref><offsets xml_i="9079" xml_f="9080" txt_i="3980" txt_f="3981">,</offsets><xref rid="bib21" ref-type="bibr"><offsets xml_i="9114" xml_f="9116" txt_i="3981" txt_f="3983">21</offsets></xref></sup></p><p><offsets xml_i="9136" xml_f="9540" txt_i="3984" txt_f="4388">Extended-release CD-LD (IPX066, RYTARY, NUMIENT; Impax Laboratories, Inc, Hayward, Calif) is an oral CD-LD formulation that combines IR and ER components with the goal of more sustained plasma LD concentrations. Extended-release CD-LD pharmacokinetic studies have shown that LD plasma concentrations rise to a typical therapeutic range within 1 hour after oral dosing and are maintained for 4 to 6 hours.</offsets><sup><xref rid="bib22" ref-type="bibr"><offsets xml_i="9579" xml_f="9581" txt_i="4388" txt_f="4390">22</offsets></xref><offsets xml_i="9588" xml_f="9589" txt_i="4390" txt_f="4391">,</offsets><xref rid="bib23" ref-type="bibr"><offsets xml_i="9623" xml_f="9625" txt_i="4391" txt_f="4393">23</offsets></xref></sup><offsets xml_i="9638" xml_f="9780" txt_i="4393" txt_f="4535"> The safety and efficacy of ER CD-LD in patients with advanced PD have been evaluated in 2 multicenter, randomized, phase 3 trials (ADVANCE-PD</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="9819" xml_f="9821" txt_i="4535" txt_f="4537">24</offsets></xref></sup><offsets xml_i="9834" xml_f="9848" txt_i="4537" txt_f="4551"> and ASCEND-PD</offsets><sup><xref rid="bib25" ref-type="bibr"><offsets xml_i="9887" xml_f="9889" txt_i="4551" txt_f="4553">25</offsets></xref></sup><offsets xml_i="9902" xml_f="10113" txt_i="4553" txt_f="4764">). In each of these trials, patients treated with ER CD-LD had less “off” time and more “on” time without troublesome dyskinesia and had improved UPDRS Parts II + III scores compared with patients given IR CD-LD</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="10152" xml_f="10154" txt_i="4764" txt_f="4766">24</offsets></xref></sup><offsets xml_i="10167" xml_f="10202" txt_i="4766" txt_f="4801"> or IR CD-LD plus entacapone (CLE).</offsets><sup><xref rid="bib25" ref-type="bibr"><offsets xml_i="10241" xml_f="10243" txt_i="4801" txt_f="4803">25</offsets></xref></sup><offsets xml_i="10256" xml_f="10557" txt_i="4803" txt_f="5104"> Because a significant proportion of these advanced PD patients were receiving adjunctive PD therapies, we performed a post hoc analysis of data from these trials to evaluate if the efficacy and safety of ER CD-LD relative to the respective active comparators were affected by concomitant medications.</offsets></p><sec sec-type="methods"><title><offsets xml_i="10592" xml_f="10599" txt_i="5105" txt_f="5112">METHODS</offsets></title><sec><title><offsets xml_i="10619" xml_f="10641" txt_i="5113" txt_f="5135">Original Trial Designs</offsets></title><p><offsets xml_i="10652" xml_f="10770" txt_i="5136" txt_f="5254">The study designs and protocols of the trials from which the current data were obtained have been published in detail.</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="10809" xml_f="10811" txt_i="5254" txt_f="5256">24</offsets></xref><offsets xml_i="10818" xml_f="10819" txt_i="5256" txt_f="5257">,</offsets><xref rid="bib25" ref-type="bibr"><offsets xml_i="10853" xml_f="10855" txt_i="5257" txt_f="5259">25</offsets></xref></sup><offsets xml_i="10868" xml_f="11445" txt_i="5259" txt_f="5836"> ADVANCE-PD and ASCEND-PD were phase 3, multinational, randomized, double-blind, double-dummy trials; ADVANCE-PD was a parallel-group study to assess the safety and efficacy of ER CD-LD versus IR CD-LD, whereas ASCEND-PD was a crossover study to evaluate ER CD-LD versus CLE. The primary clinical end point in both studies was “off” time as a percentage of waking hours. Both studies were performed in accordance with the Declaration of Helsinki. All sites received institutional review board approval, and each patient provided written informed consent prior to participation.</offsets></p><p><offsets xml_i="11452" xml_f="11634" txt_i="5837" txt_f="6019">Safety was evaluated in all patients who received at least 1 dose of any study medication. Treatment-emergent adverse events (AEs) and serious AEs were recorded throughout the study.</offsets></p></sec><sec><title><offsets xml_i="11656" xml_f="11674" txt_i="6021" txt_f="6039">Study Participants</offsets></title><p><offsets xml_i="11685" xml_f="12059" txt_i="6040" txt_f="6414">Eligible patients had idiopathic PD (Hoehn and Yahr stage ≤4 in the “on” state), with motor fluctuations (≥2.5 hours of “off” time/d) despite taking equal to or greater than 400 mg LD/d in 4 doses or more per day, and a Mini-Mental State Examination score of 26 or greater. At enrollment, patients had at least 4 weeks of unchanged treatment with either an LD IR formulation</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="12098" xml_f="12100" txt_i="6414" txt_f="6416">24</offsets></xref></sup><offsets xml_i="12113" xml_f="12120" txt_i="6416" txt_f="6423"> or CLE</offsets><sup><xref rid="bib25" ref-type="bibr"><offsets xml_i="12159" xml_f="12161" txt_i="6423" txt_f="6425">25</offsets></xref></sup><offsets xml_i="12174" xml_f="12668" txt_i="6425" txt_f="6919"> at a dosing frequency of 4 or more times per day. Concomitant use of dopaminergic agonists, MAO-B inhibitors, amantadine, or anticholinergic drugs was permitted if doses were stable for at least 4 weeks prior to study entry. Key exclusion criteria included atypical or secondary parkinsonism, history of lack of response to LD, prior neurosurgical treatment for PD, severe dyskinesia, active psychosis (or treatment with antipsychotic medications), or prior participation in an ER CD-LD study.</offsets></p></sec><sec><title><offsets xml_i="12690" xml_f="12698" txt_i="6921" txt_f="6929">Analysis</offsets></title><sec><title><offsets xml_i="12718" xml_f="12726" txt_i="6930" txt_f="6938">Efficacy</offsets></title><p><offsets xml_i="12737" xml_f="13453" txt_i="6939" txt_f="7655">In each study, the randomized patient population was divided into 3 subgroups based on the use of concomitant medications at study entry: a dopaminergic agonist group, a MAO-B inhibitor group (rasagiline and selegiline), and an amantadine group. Patients could be receiving more than 1 of these adjunctive medications concurrently, and these patients were included in more than 1 subgroup for analysis. For each subgroup, the changes from baseline in PD diary measures (“off” time and “on” time with and without troublesome dyskinesia) and UPDRS sum of Parts II (activities of daily living) and III (motor examination) scores in the “on” state were analyzed, comparing ER CD-LD with the respective active comparator.</offsets></p></sec></sec><sec><title><offsets xml_i="13481" xml_f="13496" txt_i="7658" txt_f="7673">Safety Measures</offsets></title><p><offsets xml_i="13507" xml_f="13603" txt_i="7674" txt_f="7770">Adverse event rates for the overall studies are reported in the primary articles for each study.</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="13642" xml_f="13644" txt_i="7770" txt_f="7772">24</offsets></xref><offsets xml_i="13651" xml_f="13652" txt_i="7772" txt_f="7773">,</offsets><xref rid="bib25" ref-type="bibr"><offsets xml_i="13686" xml_f="13688" txt_i="7773" txt_f="7775">25</offsets></xref></sup><offsets xml_i="13701" xml_f="13881" txt_i="7775" txt_f="7955"> Adverse events reported by 4% or more of patients during the double-blind portions of each study are reported for each treatment group within each concomitant medication subgroup.</offsets></p></sec><sec><title><offsets xml_i="13903" xml_f="13923" txt_i="7957" txt_f="7977">Statistical Analyses</offsets></title><p><offsets xml_i="13934" xml_f="14351" txt_i="7978" txt_f="8395">Post hoc analyses of the changes from baseline in PD diary measures and UPDRS Parts II and III scores at end of study were performed using a 2-way analysis of variance with subgroup variables of concomitant medication (with or without) and study treatment (ER CD-LD vs IR CD-LD or ER CD-LD vs CLE). Because of the exploratory nature of these analyses, no corrections or adjustments were made for multiple comparisons.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="14398" xml_f="14405" txt_i="8398" txt_f="8405">RESULTS</offsets></title><sec sec-type="subjects"><title><offsets xml_i="14445" xml_f="14465" txt_i="8406" txt_f="8426">Patient Demographics</offsets></title><p><offsets xml_i="14476" xml_f="14521" txt_i="8427" txt_f="8472">Patient demographics are summarized in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="14553" xml_f="14554" txt_i="8472" txt_f="8473">1</offsets></xref><offsets xml_i="14561" xml_f="14788" txt_i="8473" txt_f="8700">. Totals of 393 and 91 patients were randomized in ADVANCE-PD and ASCEND-PD, respectively. Age, duration of PD, and duration of LD treatment were similar between or within studies according to concomitant medication use (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="14820" xml_f="14821" txt_i="8700" txt_f="8701">1</offsets></xref><offsets xml_i="14828" xml_f="15127" txt_i="8701" txt_f="9000">). Of the patients randomized, at least 50% in both studies received a concomitant dopaminergic agonist. Fewer than 25% of patients took amantadine in either trial. Fewer than 25% of patients took selegiline or rasagiline in ADVANCE-PD, whereas 35% of patients took either one of these in ASCEND-PD.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15175" xml_f="15182" txt_i="9001" txt_f="9008">TABLE 1</offsets></label><caption><p><offsets xml_i="15202" xml_f="15268" txt_i="9008" txt_f="9074">Patient Demographics, and Baseline ER CD-LD Dosing Characteristics</offsets></p></caption><graphic xlink:href="wnf-41-47-g001"></graphic></table-wrap><p><offsets xml_i="15345" xml_f="16105" txt_i="9075" txt_f="9835">Overall, there were more terminations in the ER CD-LD group (7.5% overall) when compared with those taking IR CD-LD (5.2% overall) and when taking a concomitant medication of the same class. Most of this difference could be accounted for by greater numbers of subjects voluntarily withdrawing from the study rather than by other factors. The number withdrawing because of AEs was similar between subgroups in ADVANCE-PD, 9 patients each for both ER CD-LD and IR CD-LD (1.5% overall for ER CD-LD vs 1.6% for IR CD-LD). The numbers of discontinuations were similar between subgroups when there was no concomitant medication. There were only 4 early discontinuations in the ASCEND-PD study overall (all in the ER CD-LD subgroup), so no pattern could be discerned.</offsets></p><p><offsets xml_i="16112" xml_f="16559" txt_i="9836" txt_f="10283">Levodopa doses given at baseline and after dose conversion were, in general, similar among subgroups. The mean daily dose (mg LD/d) conversion ratio of ER CD-LD to IR CD-LD was 2.0 to 2.1, depending on the concomitant medication subgroup, and for ER CD-LD to CLE, it was 2.5 to 2.9. The dosing frequencies were 3.6 and 3.5 doses/d for the ER CD-LD formulation compared with the 5 doses/d for the IR CD-LD and CLE formulations, respectively (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16591" xml_f="16592" txt_i="10283" txt_f="10284">1</offsets></xref><offsets xml_i="16599" xml_f="16601" txt_i="10284" txt_f="10286">).</offsets></p></sec><sec><title><offsets xml_i="16623" xml_f="16649" txt_i="10288" txt_f="10314">Baseline PD Diary Measures</offsets></title><p><offsets xml_i="16660" xml_f="16729" txt_i="10315" txt_f="10384">Parkinson disease diary measures at baseline are summarized in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="16761" xml_f="16762" txt_i="10384" txt_f="10385">2</offsets></xref><offsets xml_i="16769" xml_f="17178" txt_i="10385" txt_f="10794">. In both studies, the ranges at baseline of mean daily “off” time, “on” time without troublesome dyskinesia, and “on” time with troublesome dyskinesia were 5.6 to 6.4 h/d, 9.7 to 10.3 h/d, and 0.2 to 0.8 h/d, respectively. There were no differences between baseline values for patients randomized to ER CD-LD versus IR CD-LD or ER CD-LD versus CLE with or without any of the concomitant medication subgroups.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="17226" xml_f="17233" txt_i="10795" txt_f="10802">TABLE 2</offsets></label><caption><p><offsets xml_i="17253" xml_f="17353" txt_i="10802" txt_f="10902">Baseline PD Diary Measures and UPDRS Parts II and III Scores by Subgroup in ADVANCE-PD and ASCEND-PD</offsets></p></caption><graphic xlink:href="wnf-41-47-g002"></graphic></table-wrap></sec><sec><title><offsets xml_i="17445" xml_f="17489" txt_i="10904" txt_f="10948">Effects of Concomitant Dopaminergic Agonists</offsets></title><p><offsets xml_i="17500" xml_f="17649" txt_i="10949" txt_f="11098">The decrease from baseline to end of double-blind treatment in “off” time was significantly greater in patients given ER CD-LD versus IR CD-LD (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="17679" xml_f="17680" txt_i="11098" txt_f="11099">1</offsets></xref><offsets xml_i="17687" xml_f="17719" txt_i="11099" txt_f="11131">A) or ER CD-LD versus CLE (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="17749" xml_f="17750" txt_i="11131" txt_f="11132">1</offsets></xref><offsets xml_i="17757" xml_f="17947" txt_i="11132" txt_f="11322">D) with or without concomitant dopaminergic agonist administration. The improvement in “on” time without troublesome dyskinesia was significantly greater with ER CD-LD versus IR CD-LD (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="17977" xml_f="17978" txt_i="11322" txt_f="11323">1</offsets></xref><offsets xml_i="17985" xml_f="18035" txt_i="11323" txt_f="11373">B; ADVANCE-PD) and with ER CD-LD versus CLE (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="18065" xml_f="18066" txt_i="11373" txt_f="11374">1</offsets></xref><offsets xml_i="18073" xml_f="18327" txt_i="11374" txt_f="11628">E; ASCEND-PD) in patients receiving a concomitant dopaminergic agonist. The increase in “on” time without troublesome dyskinesia with ER CD-LD in patients not taking a concomitant dopaminergic agonist was significantly greater only versus IR CD-LD (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="18357" xml_f="18358" txt_i="11628" txt_f="11629">1</offsets></xref><offsets xml_i="18365" xml_f="18538" txt_i="11629" txt_f="11802">B). Relative to each study comparator, ER CD-LD did not significantly worsen “on” time with troublesome dyskinesia with or without a concomitant dopaminergic agonist (Figs. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="18568" xml_f="18569" txt_i="11802" txt_f="11803">1</offsets></xref><offsets xml_i="18576" xml_f="18582" txt_i="11803" txt_f="11809">C, F).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="18623" xml_f="18631" txt_i="11810" txt_f="11818">FIGURE 1</offsets></label><caption><p><offsets xml_i="18651" xml_f="18983" txt_i="11818" txt_f="12150">Effect of concomitant use of a dopaminergic agonist with ER CD-LD versus IR CD-LD (A–C) and ER CD-LD versus CLE (D–F) on PD diary measures. Changes from baseline to end of double-blind treatment were assessed for “off” time (A, D), “on” time without troublesome dyskinesia (B, E), and “on” time with troublesome dyskinesia (C, F). *</offsets><italic><offsets xml_i="18991" xml_f="18992" txt_i="12150" txt_f="12151">P</offsets></italic><offsets xml_i="19001" xml_f="19075" txt_i="12151" txt_f="12222"> &lt; 0.05 versus IR CD-LD within each subgroup. Error bars represent SEM.</offsets></p></caption><graphic xlink:href="wnf-41-47-g003"></graphic></fig></sec><sec><title><offsets xml_i="19160" xml_f="19206" txt_i="12224" txt_f="12270">Effect of Concomitant Selegiline or Rasagiline</offsets></title><p><offsets xml_i="19217" xml_f="19305" txt_i="12271" txt_f="12359">Extended-release CD-LD produced significantly greater improvements in “off” time (Figs. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19335" xml_f="19336" txt_i="12359" txt_f="12360">2</offsets></xref><offsets xml_i="19343" xml_f="19404" txt_i="12360" txt_f="12421">A, D) and in “on” time without troublesome dyskinesia (Figs. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19434" xml_f="19435" txt_i="12421" txt_f="12422">2</offsets></xref><offsets xml_i="19442" xml_f="19694" txt_i="12422" txt_f="12674">B, E) versus IR CD-LD or CLE in patients with and without concomitant selegiline or rasagiline. There was no significant worsening of “on” time with troublesome dyskinesia with or without concomitant selegiline or rasagiline use in either study (Figs. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19724" xml_f="19725" txt_i="12674" txt_f="12675">2</offsets></xref><offsets xml_i="19732" xml_f="19738" txt_i="12675" txt_f="12681">C, F).</offsets></p><fig id="F2" position="float"><label><offsets xml_i="19779" xml_f="19787" txt_i="12682" txt_f="12690">FIGURE 2</offsets></label><caption><p><offsets xml_i="19807" xml_f="20141" txt_i="12690" txt_f="13024">Effect of concomitant use of selegiline or rasagiline with ER CD-LD versus IR CD-LD (A–C) and ER CD-LD versus CLE (D–F) on PD diary measures. Changes from baseline to end of double-blind treatment were assessed for “off” time (A, D), “on” time without troublesome dyskinesia (B, E), and “on” time with troublesome dyskinesia (C, F). *</offsets><italic><offsets xml_i="20149" xml_f="20150" txt_i="13024" txt_f="13025">P</offsets></italic><offsets xml_i="20159" xml_f="20233" txt_i="13025" txt_f="13096"> &lt; 0.05 versus IR CD-LD within each subgroup. Error bars represent SEM.</offsets></p></caption><graphic xlink:href="wnf-41-47-g004"></graphic></fig></sec><sec><title><offsets xml_i="20318" xml_f="20350" txt_i="13098" txt_f="13130">Effect of Concomitant Amantadine</offsets></title><p><offsets xml_i="20361" xml_f="20447" txt_i="13131" txt_f="13217">Extended-release CD-LD caused significantly greater improvements in “off” time (Figs. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="20477" xml_f="20478" txt_i="13217" txt_f="13218">3</offsets></xref><offsets xml_i="20485" xml_f="20543" txt_i="13218" txt_f="13276">A, D) and “on” time without troublesome dyskinesia (Figs. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="20573" xml_f="20574" txt_i="13276" txt_f="13277">3</offsets></xref><offsets xml_i="20581" xml_f="20826" txt_i="13277" txt_f="13522">B, E) versus IR CD-LD or CLE only in patients not receiving concomitant amantadine treatment. There was no significant change in “on” time with troublesome dyskinesia with ER CD-LD, IR CD-LD, or CLE with or without concomitant amantadine (Figs. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="20856" xml_f="20857" txt_i="13522" txt_f="13523">3</offsets></xref><offsets xml_i="20864" xml_f="20870" txt_i="13523" txt_f="13529">C, F).</offsets></p><fig id="F3" position="float"><label><offsets xml_i="20911" xml_f="20919" txt_i="13530" txt_f="13538">FIGURE 3</offsets></label><caption><p><offsets xml_i="20939" xml_f="21259" txt_i="13538" txt_f="13858">Effect of concomitant use of amantadine with ER CD-LD versus IR CD-LD (A–C) and ER CD-LD versus CLE (D–F) on PD diary measures. Changes from baseline to end of double-blind treatment were assessed for “off” time (A, D), “on” time without troublesome dyskinesia (B, E), and “on” time with troublesome dyskinesia (C, F). *</offsets><italic><offsets xml_i="21267" xml_f="21268" txt_i="13858" txt_f="13859">P</offsets></italic><offsets xml_i="21277" xml_f="21351" txt_i="13859" txt_f="13930"> &lt; 0.05 versus IR CD-LD within each subgroup. Error bars represent SEM.</offsets></p></caption><graphic xlink:href="wnf-41-47-g005"></graphic></fig></sec><sec><title><offsets xml_i="21436" xml_f="21502" txt_i="13932" txt_f="13998">Effect of Concomitant Medications on UPDRS Parts II and III Scores</offsets></title><p><offsets xml_i="21513" xml_f="21722" txt_i="13999" txt_f="14208">Decreases (improvements) in UPDRS Parts II and III scores were significantly greater with ER CD-LD versus IR CD-LD and with ER CD-LD versus CLE in patients not taking a concomitant dopaminergic agonist (Figs. </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="21752" xml_f="21753" txt_i="14208" txt_f="14209">4</offsets></xref><offsets xml_i="21760" xml_f="21799" txt_i="14209" txt_f="14248">A, D), selegiline or rasagiline (Figs. </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="21829" xml_f="21830" txt_i="14248" txt_f="14249">4</offsets></xref><offsets xml_i="21837" xml_f="21865" txt_i="14249" txt_f="14277">B, E), or amantadine (Figs. </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="21895" xml_f="21896" txt_i="14277" txt_f="14278">4</offsets></xref><offsets xml_i="21903" xml_f="22076" txt_i="14278" txt_f="14451">C, F). Significantly greater improvements in UPDRS Parts II and III scores were observed with ER CD-LD versus IR CD-LD in those patients taking a dopaminergic agonist (Fig. </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="22106" xml_f="22107" txt_i="14451" txt_f="14452">4</offsets></xref><offsets xml_i="22114" xml_f="22314" txt_i="14452" txt_f="14652">A), but not in patients taking the other concomitant medications. Relative to CLE treatment, ER CD-LD significantly improved UPDRS Parts II and III scores only in those without concomitant medication.</offsets></p><fig id="F4" position="float"><label><offsets xml_i="22355" xml_f="22363" txt_i="14653" txt_f="14661">FIGURE 4</offsets></label><caption><p><offsets xml_i="22383" xml_f="22727" txt_i="14661" txt_f="15005">Effect of concomitant use of medications with ER CD-LD versus IR CD-LD (A–C) and ER CD-LD versus CLE (D–F) on UPDRS Parts II and III scores in the “on” state. Changes from baseline to end of double-blind treatment were assessed with or without a concomitant dopaminergic agonist (A, D), selegiline or rasagiline (B, E), and amantadine (C, F). *</offsets><italic><offsets xml_i="22735" xml_f="22736" txt_i="15005" txt_f="15006">P</offsets></italic><offsets xml_i="22745" xml_f="22843" txt_i="15006" txt_f="15101"> &lt; 0.05 versus IR CD-LD within each subgroup. Error bars represent SEM. MAO, monoamine oxidase.</offsets></p></caption><graphic xlink:href="wnf-41-47-g006"></graphic></fig></sec><sec><title><offsets xml_i="22928" xml_f="22934" txt_i="15103" txt_f="15109">Safety</offsets></title><p><offsets xml_i="22945" xml_f="22989" txt_i="15110" txt_f="15154">Summaries of safety data are shown in Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="23021" xml_f="23022" txt_i="15154" txt_f="15155">3</offsets></xref><offsets xml_i="23029" xml_f="23053" txt_i="15155" txt_f="15179"> (ADVANCE-PD) and Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="23085" xml_f="23086" txt_i="15179" txt_f="15180">4</offsets></xref><offsets xml_i="23093" xml_f="23106" txt_i="15180" txt_f="15193"> (ASCEND-PD).</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="23154" xml_f="23161" txt_i="15194" txt_f="15201">TABLE 3</offsets></label><caption><p><offsets xml_i="23181" xml_f="23301" txt_i="15201" txt_f="15321">Adverse Events Reported in 4% or More of Patients in Any Subgroup During the Double-blind Treatment Period in ADVANCE-PD</offsets></p></caption><graphic xlink:href="wnf-41-47-g007"></graphic></table-wrap><table-wrap id="T4" position="float"><label><offsets xml_i="23419" xml_f="23426" txt_i="15322" txt_f="15329">TABLE 4</offsets></label><caption><p><offsets xml_i="23446" xml_f="23565" txt_i="15329" txt_f="15448">Adverse Events Reported in 4% or More of Patients in Any Subgroup During the Double-blind Treatment Period in ASCEND-PD</offsets></p></caption><graphic xlink:href="wnf-41-47-g008"></graphic></table-wrap><p><offsets xml_i="23642" xml_f="23819" txt_i="15449" txt_f="15626">The overall percentage of AEs for those patients taking concomitant medications was similar for ER LD-CD and IR CD-LD groups in ADVANCE-PD and for ER LD-CD and CLE in ASCEND-PD.</offsets></p><p><offsets xml_i="23826" xml_f="24320" txt_i="15627" txt_f="16121">For those taking concomitant medications, there were higher incidences of dyskinesia and falls in the ER CD-LD group versus the IR CD-LD group, even though the overall numbers were low. The dyskinesia rate was higher for the ER CD-LD group versus the CLE group only for those patients taking dopaminergic agonists or selegiline or rasagiline. Adverse events of weight decrease occurred in the ER CD-LD with concomitant medication groups, and these were absent in the equivalent IR CD-LD groups.</offsets></p><p><offsets xml_i="24327" xml_f="24391" txt_i="16122" txt_f="16186">Overall serious AEs have been reported in previous publications.</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="24430" xml_f="24432" txt_i="16186" txt_f="16188">24</offsets></xref><offsets xml_i="24439" xml_f="24440" txt_i="16188" txt_f="16189">,</offsets><xref rid="bib25" ref-type="bibr"><offsets xml_i="24474" xml_f="24476" txt_i="16189" txt_f="16191">25</offsets></xref></sup><offsets xml_i="24489" xml_f="24860" txt_i="16191" txt_f="16562"> In ADVANCE-PD, during the double-blind treatment period, 11 patients (5%) in the ER CD-LD group reported 13 serious AEs. In the IR CD-LD group, there were 5 patients (3%) who experienced 8 serious AEs. In ASCEND-PD, only 1 serious AE (sciatica) occurred during double-blind treatment in an ER CD-LD patient who was also taking a dopaminergic agonist and a MAO inhibitor.</offsets><sup><xref rid="bib25" ref-type="bibr"><offsets xml_i="24899" xml_f="24901" txt_i="16562" txt_f="16564">25</offsets></xref></sup><offsets xml_i="24914" xml_f="25121" txt_i="16564" txt_f="16771"> The low number of serious AEs and absence of any clear pattern did not allow for meaningful comparisons to be made between subgroups. For any subgroup, only a single occurrence of each AE type was observed.</offsets></p></sec></sec><sec sec-type="discussions"><title><offsets xml_i="25172" xml_f="25182" txt_i="16774" txt_f="16784">DISCUSSION</offsets></title><p><offsets xml_i="25193" xml_f="26127" txt_i="16785" txt_f="17719">Relative to both comparator therapies, treatment with ER CD-LD was associated with improvement in the key patient diary measures (“off” and “on” time without troublesome dyskinesia), regardless of whether the patient was taking a dopaminergic agonist or a MAO-B inhibitor. Numerical improvements by ER CD-LD versus each comparator were observed in patients treated with concomitant amantadine, but these were not statistically significant in either study. Relative to each comparator and with all the concomitant medication subgroups, ER CD-LD was not associated with worsening of troublesome dyskinesia. Results of the UPDRS Parts II and III showed similar trends to findings from the PD diary in favor of ER CD-LD. Extended-release CD-LD treatment consistently improved scores compared with IR CD-LD and CLE; however, the numerical improvement was not statistically significant in patients receiving a MAO-B inhibitor or amantadine.</offsets></p><p><offsets xml_i="26134" xml_f="26355" txt_i="17720" txt_f="17941">The final dose ratio of preconversion and postconversion to ER CD-LD from IR CD-LD were all 2.0 to 2.1, whereas from CLE the ratio was 2.7 to 2.9 for the subgroups except for the amantadine group, where the ratio was 2.5.</offsets></p><p><offsets xml_i="26362" xml_f="26407" txt_i="17942" txt_f="17987">Studies have shown that dopaminergic agonists</offsets><sup><xref rid="bib26" ref-type="bibr"><offsets xml_i="26446" xml_f="26448" txt_i="17987" txt_f="17989">26</offsets></xref><offsets xml_i="26455" xml_f="26456" txt_i="17989" txt_f="17990">–</offsets><xref rid="bib28" ref-type="bibr"><offsets xml_i="26490" xml_f="26492" txt_i="17990" txt_f="17992">28</offsets></xref></sup><offsets xml_i="26505" xml_f="26526" txt_i="17992" txt_f="18013"> and MAO-B inhibitors</offsets><sup><xref rid="bib29" ref-type="bibr"><offsets xml_i="26565" xml_f="26567" txt_i="18013" txt_f="18015">29</offsets></xref><offsets xml_i="26574" xml_f="26575" txt_i="18015" txt_f="18016">–</offsets><xref rid="bib31" ref-type="bibr"><offsets xml_i="26609" xml_f="26611" txt_i="18016" txt_f="18018">31</offsets></xref></sup><offsets xml_i="26624" xml_f="26895" txt_i="18018" txt_f="18289"> are effective as monotherapy for the control of motor symptoms. However, their effectiveness in patients with advanced PD has been examined only as adjunct therapies to LD. These drug classes can improve UPDRS Parts II and III scores and reduce the amount of “off” time.</offsets><sup><xref rid="bib7" ref-type="bibr"><offsets xml_i="26933" xml_f="26934" txt_i="18289" txt_f="18290">7</offsets></xref><offsets xml_i="26941" xml_f="26942" txt_i="18290" txt_f="18291">–</offsets><xref rid="bib16" ref-type="bibr"><offsets xml_i="26976" xml_f="26978" txt_i="18291" txt_f="18293">16</offsets></xref><offsets xml_i="26985" xml_f="26986" txt_i="18293" txt_f="18294">,</offsets><xref rid="bib32" ref-type="bibr"><offsets xml_i="27020" xml_f="27022" txt_i="18294" txt_f="18296">32</offsets></xref></sup><offsets xml_i="27035" xml_f="28164" txt_i="18296" txt_f="19425"> Thus, it is conceivable that differences in the efficacy of ER CD-LD versus IR CD-LD or CLE found in the ADVANCE-PD and ASCEND-PD trials may have been lessened in those patients who received concomitant dopaminergic agonist or MAO-B inhibitor therapy. Our analysis shows the opposite; namely, improvements in PD diary measures afforded by ER CD-LD versus IR CD-LD or CLE were not diminished by the concomitant administration of these classes of medication. Differences in UPDRS Parts II and III scores were statistically significant only in the ADVANCE-PD trial in patients receiving a concomitant dopaminergic agonist. Explanations for this observation may be related to the smaller overall change in UPDRS scores in the ASCEND-PD trial compared with improvements in ADVANCE-PD (due possibly to the shorter treatment duration). In addition, the between-treatment-groups differences in UPDRS II + III were relatively small compared with those observed in the patient diary measures, so when the study was subdivided, it should not be surprising that the statistical significance of some of the subgroup differences had declined.</offsets></p><p><offsets xml_i="28171" xml_f="28312" txt_i="19426" txt_f="19567">Amantadine is commonly prescribed as a mild antiparkinsonian medication or as an adjunctive therapy to treat tremor or LD-induced dyskinesia,</offsets><sup><xref rid="bib6" ref-type="bibr"><offsets xml_i="28350" xml_f="28351" txt_i="19567" txt_f="19568">6</offsets></xref><offsets xml_i="28358" xml_f="28359" txt_i="19568" txt_f="19569">,</offsets><xref rid="bib33" ref-type="bibr"><offsets xml_i="28393" xml_f="28395" txt_i="19569" txt_f="19571">33</offsets></xref></sup><offsets xml_i="28408" xml_f="28457" txt_i="19571" txt_f="19620"> and it has also been shown to reduce “off” time.</offsets><sup><xref rid="bib34" ref-type="bibr"><offsets xml_i="28496" xml_f="28498" txt_i="19620" txt_f="19622">34</offsets></xref></sup><offsets xml_i="28511" xml_f="28725" txt_i="19622" txt_f="19836"> Concomitant use of amantadine with ER CD-LD produced a numerical decrease in “off” time and an increase in “on” time without troublesome dyskinesia compared with IR CD-LD, but this difference was not significant (</offsets><italic><offsets xml_i="28733" xml_f="28734" txt_i="19836" txt_f="19837">P</offsets></italic><offsets xml_i="28743" xml_f="28754" txt_i="19837" txt_f="19848"> = 0.5 and </offsets><italic><offsets xml_i="28762" xml_f="28763" txt_i="19848" txt_f="19849">P</offsets></italic><offsets xml_i="28772" xml_f="29052" txt_i="19849" txt_f="20129"> = 0.65, respectively). This may be due to inherent differences in those patients who require amantadine treatment for their dyskinesia such that it affects their LD response or may reflect the smaller sample size of the subgroups compared with the dopaminergic agonist subgroups.</offsets></p><p><offsets xml_i="29059" xml_f="29140" txt_i="20130" txt_f="20211">The overall safety profile was not altered by the use of concomitant medications.</offsets><sup><xref rid="bib24" ref-type="bibr"><offsets xml_i="29179" xml_f="29181" txt_i="20211" txt_f="20213">24</offsets></xref><offsets xml_i="29188" xml_f="29189" txt_i="20213" txt_f="20214">,</offsets><xref rid="bib25" ref-type="bibr"><offsets xml_i="29223" xml_f="29225" txt_i="20214" txt_f="20216">25</offsets></xref></sup><offsets xml_i="29238" xml_f="29316" txt_i="20216" txt_f="20294"> Dyskinesia is a well documented adverse effect of all dopaminergic therapies.</offsets><sup><xref rid="bib8" ref-type="bibr"><offsets xml_i="29354" xml_f="29355" txt_i="20294" txt_f="20295">8</offsets></xref><offsets xml_i="29362" xml_f="29363" txt_i="20295" txt_f="20296">,</offsets><xref rid="bib9" ref-type="bibr"><offsets xml_i="29396" xml_f="29397" txt_i="20296" txt_f="20297">9</offsets></xref><offsets xml_i="29404" xml_f="29405" txt_i="20297" txt_f="20298">,</offsets><xref rid="bib11" ref-type="bibr"><offsets xml_i="29439" xml_f="29441" txt_i="20298" txt_f="20300">11</offsets></xref><offsets xml_i="29448" xml_f="29449" txt_i="20300" txt_f="20301">,</offsets><xref rid="bib32" ref-type="bibr"><offsets xml_i="29483" xml_f="29485" txt_i="20301" txt_f="20303">32</offsets></xref></sup><offsets xml_i="29498" xml_f="29948" txt_i="20303" txt_f="20753"> In the present study, there was an increased incidence of dyskinesia (reported as an AE) with ER CD-LD for those taking concomitant dopaminergic agonists and selegiline or rasagiline compared with prior regimens of IR CD-LD and CLE. However, the overall reporting rates for dyskinesia were low and did not translate into a significant increase in “on” time with troublesome dyskinesia (per patient diaries) for either of these concomitant therapies.</offsets></p><p><offsets xml_i="29955" xml_f="30428" txt_i="20754" txt_f="21227">A limitation of the present analysis is that some of the patients may have received more than 1 class of concomitant therapy. Thus, the effects observed by one class may not be independent of the effects caused by the others and may be the result of interactions between the different classes. However, limiting patient selection to those given only 1 of the 3 classes used in the present analysis may have yielded sample sizes too low to allow for conclusions to be drawn.</offsets></p><p><offsets xml_i="30435" xml_f="30889" txt_i="21228" txt_f="21682">In conclusion, the use of a concomitant dopaminergic agonist or MAO-B inhibitor did not diminish the efficacy of ER CD-LD compared with IR CD-LD or CLE, whereas the improvement observed with concomitant amantadine failed to reach statistical significance. Treatment with ER CD-LD also did not increase troublesome dyskinesia compared with IR CD-LD or CLE for any of the studied subgroups. Safety and tolerability were similar among the patient subgroups.</offsets></p></sec></body><back><fn-group><fn fn-type="supported-by"><p>These studies were funded by Impax Laboratories, Inc. Medical writing support was provided by Gerard D'Angelo, PhD, and Robin Smith, PhD, of The Curry Rockefeller Group, LLC, supported by Impax Laboratories, Inc.</p></fn><fn fn-type="other"><p>P.A.L. and L.V.M. have served as consultants and have been investigators in clinical trials sponsored by Impax Laboratories, Inc. P.A.L. has also served as a consultant or advisor for Britannia, Acorda, Concit, Dexcel, Depomed, Insightec, Intec, Ipsen, Merck, Merz, NeuroDerm, Noven, Parkinson Study Group, Pfizer, ProStrakan, Teva, and US WorldMeds and has received speaker honoraria from the International Parkinson's Disease and Movement Disorders Society, Lundbeck, US WorldMeds, and the World Parkinson Congress. H<italic>Clinical Neuropharmacology</italic> and serves without compensation on the editorial boards of <italic>Journal of Neural Transmission</italic>, <italic>Translational Neurodegeneration</italic>, and <italic>Journal of Parkinson's Disease</italic>. The Parkinson's Disease and Movement Disorders Program that P.A.L. directs has received clinical research grant support (for conducting clinical trial and other research) from Acorda, Adamas, Biotie, Great Lakes Neurotechnologies, Kyowa, The Michael J. Fox Foundation for Parkinson's Research, Pharma 2B, and US WorldMeds. L.V.M. received compensation from Medtronic, St Jude Medical, Britannia, US WorldMeds, and Cynapsus for consulting services. He has also received financial support for research activities from Medtronic, Boston Scientific, Adamas, Osmotica, Pfizer, US WorldMeds, National Institutes of Health, and Michael J Fox Foundation, in a role as principal investigator for research studies. R.R., S. Khanna, S. Kell, and S.G. are employees of Impax Laboratories, Inc, and hold Impax stock and/or stock options.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="bib1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>LeWitt</surname><given-names>PA</given-names></name></person-group>
<article-title>Levodopa for the treatment of Parkinson's disease</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2008</year>;<volume>359</volume>(<issue>23</issue>):<fpage>2468</fpage>–<lpage>2476</lpage>.<pub-id pub-id-type="pmid">19052127</pub-id></mixed-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>LeWitt</surname><given-names>PA</given-names></name></person-group>
<article-title>Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics</article-title>. <source><italic>Mov Disord</italic></source>
<year>2015</year>;<volume>30</volume>(<issue>1</issue>):<fpage>64</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">25449210</pub-id></mixed-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Di Filippo</surname><given-names>M</given-names></name><name><surname>Ghiglieri</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>Molecular mechanisms underlying levodopa-induced dyskinesia</article-title>. <source><italic>Mov Disord</italic></source>
<year>2008</year>;<volume>23</volume>(<issue>Suppl 3</issue>):<fpage>S570</fpage>–<lpage>S579</lpage>.<pub-id pub-id-type="pmid">18781674</pub-id></mixed-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Metman</surname><given-names>LV</given-names></name><name><surname>Konitsiotis</surname><given-names>S</given-names></name><name><surname>Chase</surname><given-names>TN</given-names></name></person-group>
<article-title>Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what</article-title>. <source><italic>Mov Disord</italic></source>
<year>2000</year>;<volume>15</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">10634235</pub-id></mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Connolly</surname><given-names>BS</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name></person-group>
<article-title>Pharmacological treatment of Parkinson disease: a review</article-title>. <source><italic>JAMA</italic></source>
<year>2014</year>;<volume>311</volume>(<issue>16</issue>):<fpage>1670</fpage>–<lpage>1683</lpage>.<pub-id pub-id-type="pmid">24756517</pub-id></mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Ferreira</surname><given-names>JJ</given-names></name><name><surname>Katzenschlager</surname><given-names>R</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><etal></etal></person-group>
<article-title>Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease</article-title>. <source><italic>Eur J Neurol</italic></source>
<year>2013</year>;<volume>20</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">23279439</pub-id></mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Guttman</surname><given-names>M</given-names></name></person-group>
<article-title>Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group</article-title>. <source><italic>Neurology</italic></source>
<year>1997</year>;<volume>49</volume>(<issue>4</issue>):<fpage>1060</fpage>–<lpage>1065</lpage>.<pub-id pub-id-type="pmid">9339690</pub-id></mixed-citation></ref><ref id="bib8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Lieberman</surname><given-names>A</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Sethi</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group</article-title>. <source><italic>Neurology</italic></source>
<year>1998</year>;<volume>51</volume>(<issue>4</issue>):<fpage>1057</fpage>–<lpage>1062</lpage>.<pub-id pub-id-type="pmid">9781529</pub-id></mixed-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Lieberman</surname><given-names>A</given-names></name><name><surname>Ranhosky</surname><given-names>A</given-names></name><name><surname>Korts</surname><given-names>D</given-names></name></person-group>
<article-title>Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study</article-title>. <source><italic>Neurology</italic></source>
<year>1997</year>;<volume>49</volume>(<issue>1</issue>):<fpage>162</fpage>–<lpage>168</lpage>.<pub-id pub-id-type="pmid">9222185</pub-id></mixed-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Senard</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>A placebo-controlled study of ropinirole, a new D<sub>2</sub> agonist, in the treatment of motor fluctuations of <sc>l</sc>-DOPA–treated parkinsonian patients</article-title>. <source><italic>Adv Neurol</italic></source>
<year>1996</year>;<volume>69</volume>:<fpage>531</fpage>–<lpage>534</lpage>.<pub-id pub-id-type="pmid">8615176</pub-id></mixed-citation></ref><ref id="bib11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Moller</surname><given-names>JC</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Koster</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial</article-title>. <source><italic>Mov Disord</italic></source>
<year>2005</year>;<volume>20</volume>(<issue>5</issue>):<fpage>602</fpage>–<lpage>610</lpage>.<pub-id pub-id-type="pmid">15726540</pub-id></mixed-citation></ref><ref id="bib12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Ellis</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease</article-title>. <source><italic>Mov Disord</italic></source>
<year>2007</year>;<volume>22</volume>(<issue>4</issue>):<fpage>483</fpage>–<lpage>489</lpage>.<pub-id pub-id-type="pmid">17115380</pub-id></mixed-citation></ref><ref id="bib13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study</article-title>. <source><italic>Mov Disord</italic></source>
<year>2007</year>;<volume>22</volume>(<issue>13</issue>):<fpage>1860</fpage>–<lpage>1865</lpage>.<pub-id pub-id-type="pmid">17618525</pub-id></mixed-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="journal"><collab collab-type="author">Parkinson Study Group</collab>. <article-title>A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study</article-title>. <source><italic>Arch Neurol</italic></source>
<year>2005</year>;<volume>62</volume>(<issue>2</issue>):<fpage>241</fpage>–<lpage>248</lpage>.<pub-id pub-id-type="pmid">15710852</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial</article-title>. <source><italic>Lancet</italic></source>
<year>2005</year>;<volume>365</volume>(<issue>9463</issue>):<fpage>947</fpage>–<lpage>954</lpage>.<pub-id pub-id-type="pmid">15766996</pub-id></mixed-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Waters</surname><given-names>CH</given-names></name><name><surname>Sethi</surname><given-names>KD</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><etal></etal></person-group>
<article-title>Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study</article-title>. <source><italic>Mov Disord</italic></source>
<year>2004</year>;<volume>19</volume>(<issue>4</issue>):<fpage>426</fpage>–<lpage>432</lpage>.<pub-id pub-id-type="pmid">15077240</pub-id></mixed-citation></ref><ref id="bib17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Luginger</surname><given-names>E</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><name><surname>Bosch</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Beneficial effects of amantadine on <sc>l</sc>-dopa-induced dyskinesias in Parkinson's disease</article-title>. <source><italic>Mov Disord</italic></source>
<year>2000</year>;<volume>15</volume>(<issue>5</issue>):<fpage>873</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">11009193</pub-id></mixed-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Metman</surname><given-names>LV</given-names></name><name><surname>Del Dotto</surname><given-names>P</given-names></name><name><surname>LePoole</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study</article-title>. <source><italic>Arch Neurol</italic></source>
<year>1999</year>;<volume>56</volume>(<issue>11</issue>):<fpage>1383</fpage>–<lpage>1386</lpage>.<pub-id pub-id-type="pmid">10555659</pub-id></mixed-citation></ref><ref id="bib19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Verhagen Metman</surname><given-names>L</given-names></name><name><surname>Del Dotto</surname><given-names>P</given-names></name><name><surname>van den Munckhof</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease</article-title>. <source><italic>Neurology</italic></source>
<year>1998</year>;<volume>50</volume>(<issue>5</issue>):<fpage>1323</fpage>–<lpage>1326</lpage>.<pub-id pub-id-type="pmid">9595981</pub-id></mixed-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Stowe</surname><given-names>R</given-names></name><name><surname>Ives</surname><given-names>N</given-names></name><name><surname>Clarke</surname><given-names>CE</given-names></name><etal></etal></person-group>
<article-title>Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications</article-title>. <source><italic>Cochrane Database Syst Rev</italic></source>
<year>2010</year>(<issue>7</issue>):<fpage>CD007166</fpage>.<pub-id pub-id-type="pmid">20614454</pub-id></mixed-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Lyons</surname><given-names>KE</given-names></name><etal></etal></person-group>
<article-title>Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title>. <source><italic>Neurology</italic></source>
<year>2006</year>;<volume>66</volume>(<issue>7</issue>):<fpage>983</fpage>–<lpage>995</lpage>.<pub-id pub-id-type="pmid">16606909</pub-id></mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Ellenbogen</surname><given-names>AL</given-names></name><name><surname>Metman</surname><given-names>LV</given-names></name><etal></etal></person-group>
<article-title>Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease</article-title>. <source><italic>Mov Disord</italic></source>
<year>2011</year>;<volume>26</volume>(<issue>12</issue>):<fpage>2246</fpage>–<lpage>2252</lpage>.<pub-id pub-id-type="pmid">21755537</pub-id></mixed-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Yao</surname><given-names>HM</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Clinical pharmacokinetics of IPX066: evaluation of dose proportionality and effect of food in healthy volunteers</article-title>. <source><italic>Clin Neuropharmacol</italic></source>
<year>2016</year>;<volume>39</volume>(<issue>1</issue>):<fpage>10</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">26626430</pub-id></mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Kell</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial</article-title>. <source><italic>Lancet Neurol</italic></source>
<year>2013</year>;<volume>12</volume>(<issue>4</issue>):<fpage>346</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">23485610</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Stocchi</surname><given-names>F</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients</article-title>. <source><italic>Parkinsonism Relat Disord</italic></source>
<year>2014</year>;<volume>20</volume>(<issue>12</issue>):<fpage>1335</fpage>–<lpage>1340</lpage>.<pub-id pub-id-type="pmid">25306200</pub-id></mixed-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Holloway</surname><given-names>RG</given-names></name><name><surname>Shoulson</surname><given-names>I</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial</article-title>. <source><italic>Arch Neurol</italic></source>
<year>2004</year>;<volume>61</volume>(<issue>7</issue>):<fpage>1044</fpage>–<lpage>1053</lpage>.<pub-id pub-id-type="pmid">15262734</pub-id></mixed-citation></ref><ref id="bib27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Kieburtz</surname><given-names>K</given-names></name></person-group>
<article-title>Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial</article-title>. <source><italic>Mov Disord</italic></source>
<year>2011</year>;<volume>26</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">20925067</pub-id></mixed-citation></ref><ref id="bib28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Caldas</surname><given-names>AC</given-names></name><etal></etal></person-group>
<article-title>Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study</article-title>. <source><italic>Mov Disord</italic></source>
<year>2006</year>;<volume>21</volume>(<issue>12</issue>):<fpage>2110</fpage>–<lpage>2115</lpage>.<pub-id pub-id-type="pmid">17013922</pub-id></mixed-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Hauser</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>A double-blind, delayed-start trial of rasagiline in Parkinson's disease</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2009</year>;<volume>361</volume>(<issue>13</issue>):<fpage>1268</fpage>–<lpage>1278</lpage>.<pub-id pub-id-type="pmid">19776408</pub-id></mixed-citation></ref><ref id="bib30"><label>30</label><mixed-citation publication-type="journal"><collab collab-type="author">Parkinson Study Group</collab>. <article-title>A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease</article-title>. <source><italic>Arch Neurol</italic></source>
<year>2004</year>;<volume>61</volume>(<issue>4</issue>):<fpage>561</fpage>–<lpage>566</lpage>.<pub-id pub-id-type="pmid">15096406</pub-id></mixed-citation></ref><ref id="bib31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Marek</surname><given-names>KL</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients</article-title>. <source><italic>Mov Disord</italic></source>
<year>2004</year>;<volume>19</volume>(<issue>8</issue>):<fpage>916</fpage>–<lpage>923</lpage>.<pub-id pub-id-type="pmid">15300656</pub-id></mixed-citation></ref><ref id="bib32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Muenter</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease</article-title>. <source><italic>Mov Disord</italic></source>
<year>1994</year>;<volume>9</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">8139604</pub-id></mixed-citation></ref><ref id="bib33"><label>33</label><mixed-citation publication-type="journal"><person-group><name><surname>Schaeffer</surname><given-names>E</given-names></name><name><surname>Pilotto</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name></person-group>
<article-title>Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease</article-title>. <source><italic>CNS Drugs</italic></source>
<year>2014</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1155</fpage>–<lpage>1184</lpage>.<pub-id pub-id-type="pmid">25342080</pub-id></mixed-citation></ref><ref id="bib34"><label>34</label><mixed-citation publication-type="journal"><person-group><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><etal></etal></person-group>
<article-title>ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial</article-title>. <source><italic>JAMA Neurol</italic></source>
<year>2017</year>;<volume>74</volume>(<issue>8</issue>):<fpage>941</fpage>–<lpage>949</lpage>.<pub-id pub-id-type="pmid">28604926</pub-id></mixed-citation></ref></ref-list></back></article>